The 0.25mg Wegovy Pen: Your Starting Point, Not Your Destination

Why your prescriber starts here, not higher

A question our prescribers hear most weeks: "Can I skip the 0.25mg and start on something stronger?" The short answer is no, and the reason is practical rather than bureaucratic. Semaglutide has a well-documented early side-effect profile: nausea, loose stools, indigestion, sometimes vomiting. These are most likely to appear at the beginning of treatment or after a dose increase. Starting at 0.25mg gives your gut time to adapt before the dose rises.

This isn't guesswork. The titration schedule published in the Wegovy SmPC on the eMC exists because the clinical programme showed better tolerability when patients stepped up gradually. The 0.25mg phase typically lasts four weeks, then moves to 0.5mg, with further monthly increases until you reach the 2.4mg maintenance dose — or 7.2mg under the expanded schedule approved in 2026. You can read more about how that full journey looks on our Wegovy dose schedule overview.

One more thing worth saying plainly: if 0.25mg feels like nothing is happening, that is by design. The therapeutic effect builds with the dose. Expecting weight loss in the first four weeks often leads to unnecessary disappointment.

What the 0.25mg pen actually contains

The physical pen matters because it trips people up. Each 0.25mg Wegovy pen is pre-filled with 0.5ml of solution delivering four 0.25mg doses, one injection per week. The pen is a multi-dose device; you do not use a fresh pen for every injection. You inject once on the same day each week, cap the pen, and store it in the fridge at 2–8°C until the following week.

Some patients confuse the volume figure with the dose: 0.5ml is the total fill volume, and the 0.25ml per injection refers to the amount of liquid delivered with each use. Your prescriber and the Patient Information Leaflet will be your definitive guide on injection technique, but the mechanics are straightforward once you have done it once.

Storage outside the fridge is possible for a limited period, the exact window is specified in your leaflet and is the number you should follow, not anything quoted on a webpage. If you are unsure how many injections you have left in a pen, our guide on how many doses the 0.25mg pen contains walks through how to track usage.

Moving from 0.25mg to 0.5mg: what to weigh up

After four weeks at 0.25mg, the standard next step is 0.5mg. But the decision to increase is not automatic, it is clinical. If you are still managing significant nausea or other side effects at 0.25mg, your prescriber may advise staying there a little longer. Rushing a dose increase that your body is not ready for tends to produce worse side effects and higher drop-out rates, not faster results.

The NHS guidance on weight management injections is clear that titration should be led by tolerability, not impatience. What you are looking for before stepping up is a week or two of relative comfort at the current dose. More on reading those signals is covered in our page on knowing when to increase your Wegovy dose.

At nume, every repeat order goes through a fresh clinical review. That means a prescriber looks at your progress before the next pen is issued, not because we want to create friction, but because dose changes should be considered decisions, not automatic dispatches. If you have questions between orders, our team is available seven days a week. You can always get in touch if something feels off.

Who the 0.25mg pen is and is not suitable for

Wegovy is licensed for adults. It is not suitable for people who are pregnant, breastfeeding, or trying to conceive, or for anyone under 18. Certain medical histories (including pancreatitis and specific thyroid conditions) require careful prescriber assessment, and some medications interact with semaglutide. For women using oral contraceptives, the current guidance does not point to a meaningful interaction with semaglutide the way it does with tirzepatide, but your prescriber will factor in your full medication list.

The private eligibility thresholds broadly mirror the licence: BMI of 30 or above, or 27 or above with a qualifying weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not guarantee suitability, the prescriber reviews the whole picture. If you want to explore whether Wegovy fits your situation, the free consultation at nume is where that conversation starts, with a GPhC-registered Independent Prescriber reviewing your answers the same day.

For broader context on what the treatment involves, the Wegovy overview page covers the full picture, including a cost context section for anyone thinking about what private treatment involves financially.